Get the Stockscreener App
88.31
1.85%
1.605
Rhythm Pharmaceuticals Inc stock is traded at $88.31, with a volume of 151.26K.
It is up +1.85% in the last 24 hours and down -8.74% over the past month.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
See More
Previous Close:
$86.71
Open:
$88.41
24h Volume:
151.26K
Relative Volume:
0.18
Market Cap:
$6.08B
Revenue:
$217.17M
Net Income/Loss:
$-202.68M
P/E Ratio:
-38.35
EPS:
-2.3028
Net Cash Flow:
$-156.63M
1W Performance:
-1.48%
1M Performance:
-8.74%
6M Performance:
+0.58%
1Y Performance:
-19.24%
1-Day Range:
$87.61
$90.42
1-Week Range:
$85.38
$93.35
52-Week Range:
$74.50
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
88.31 | 6.08B | 217.17M | -202.68M | -156.63M | -2.3028 |
VRTX
Vertex Pharmaceuticals Inc
|
510.13 | 129.30B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.70 | 94.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.21 | 82.49B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.03 | 53.33B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
370.95 | 41.96B | 5.76B | 514.49M | 1.10B | 4.4813 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-26 | Initiated | Wolfe Research | Outperform |
| Sep-14-26 | Resumed | Leerink Partners | Outperform |
| Aug-28-26 | Initiated | Deutsche Bank | Hold |
| Jul-27-26 | Initiated | JP Morgan | Overweight |
| Feb-19-26 | Initiated | RBC Capital Mkts | Outperform |
| Nov-25-25 | Initiated | Citigroup | Buy |
| Nov-05-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-10-25 | Initiated | Goldman | Buy |
| Jul-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-07-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Jan-02-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Guggenheim | Buy |
| Sep-18-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | JMP Securities | Mkt Outperform |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-22 | Reiterated | Needham | Buy |
| Mar-02-22 | Resumed | Stifel | Buy |
| Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-14-21 | Resumed | Goldman | Neutral |
| Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-08-20 | Initiated | Goldman | Sell |
| Jul-12-19 | Upgrade | Stifel | Hold → Buy |
| Jul-08-19 | Initiated | Canaccord Genuity | Buy |
| Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
| Sep-07-18 | Resumed | Morgan Stanley | Overweight |
| Jun-25-18 | Reiterated | Needham | Buy |
| Jun-15-18 | Reiterated | Needham | Buy |
| Oct-30-17 | Initiated | BofA/Merrill | Buy |
| Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity - GlobeNewswire Inc.
Rhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should Know - Zacks Investment Research
Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) Share Price, RYTM Stock News, RYTM Share Price & Updates - kalkine.ca
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Rhythm Pops on Health Canada Nod - baystreet.ca
Rhythm Pops on Health Canada Nod - Baystreet.ca
RHYTHM Pharmaceuticals CEO David P. Meeker Executes Option Exercise and Sells 50,000 Shares - Kalkine Media
Rhythm Pharmaceuticals Insider Sold Shares Worth $5,133,442, According to a Recent SEC Filing - finance.yahoo.com
Rhythm Pharmaceuticals (RYTM) CEO sells 50,000 shares under preset plan - Stock Titan
Insider lines up multimillion-dollar stock sale at Rhythm Pharmaceuticals (NASDAQ: RYTM) - Stock Titan
Rhythm Pharmaceuticals president & CEO Meeker sells $5.13m stock - Investing.com
Avoiding Lag: Real-Time Signals in (RYTM) Movement - Stock Traders Daily
Obesity Market to Witness Strong Growth and Significant Market Expansion by 2036 – DelveInsight | Rhythm Pharma, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical - Barchart.com
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting - manilatimes.net
French children showed lower body-size scores on a rare-obesity drug - Stock Titan
Rhythm Pharmaceuticals at Wells Fargo conference: ho launch gains traction By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals at Wells Fargo conference: ho launch gains traction By Investing.com - Investing.com UK
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A 36.45% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
An AI drug specialist zeroes in on rare forms of obesity - BioPharma Dive
Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years - Benzinga
Rhythm Pharmaceuticals stock edges lower after insider sale but stays backed by strong Q2 growth - AD HOC NEWS
How Rhythm Pharmaceuticals Inc. (RYTM) Affects Rotational Strategy Timing - Stock Traders Daily
Rhythm Pharmaceuticals(RYTM.US) Officer Sells US$6.62 Million in Common Stock - Moomoo
Rhythm Pharmaceuticals (RYTM) CFO sells 62,774 shares in planned trade - Stock Titan
Rhythm (NASDAQ: RYTM) officer files Rule 144 stock sale notice - Stock Titan
Here's How Much $100 Invested In Rhythm Pharmaceuticals 5 Years Ago Would Be Worth Today - Benzinga
Rhythm Pharmaceuticals (RYTM): Investor Outlook on a 30.81% Potential Upside in Biotechnology - DirectorsTalk Interviews
Rhythm Pharmaceuticals Inc. (RYTM) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
RHYTHM PHARMACEUTICALS, INC. : DEUTSCHE BANK INITIATES COVERAGE WITH HOLD RATING AND TARGET PRICE $120 - webull.com
Deutsche Bank Initiates Rhythm Pharmaceuticals(RYTM.US) With Hold Rating, Announces Target Price $120 - Moomoo
ZLAB Stock Price, Quote & News - Syfe
Parabilis Medicines, Inc. (PBLS) Stock Price & News - Syfe
Deutsche Bank Initiates Rhythm Pharmaceuticals(RYTM.US) With Hold Rating, Announces Target Price $120 - Moomoo
Deutsche Bank Initiates Rhythm Pharmaceuticals at Hold With $120 Price Target - marketscreener.com
Rhythm Pharmaceuticals (RYTM) Could Be 15% Undervalued As Japan Approval Lifts Its Story - sahmcapital.com
Rhythm Pharmaceuticals Gains Japan Approval For IMCIVREE In Hypothalamic Obesity - DirectorsTalk Interviews
Rhythm Pharmaceuticals (RYTM) Stock Looks Overvalued Despite Its 7x Five Year Run - Yahoo Finance
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan - The Manila Times
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Biotechnology Innovator Seeks 28.67% Upside with Breakthrough Therapies - DirectorsTalk Interviews
Japan Grants Marketing Authorization to First Therapy for Rare Obesity Affecting 5,000–8,000 People - Stock Titan
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can - Yahoo Finance
Blue Owl Capital Holdings LP Invests $6.82 Million in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
TD Cowen Names Rhythm Pharmaceuticals Its Top Pick Following Robust Q2 Results - StockInvest.us
Rhythm Pharmaceuticals (RYTM) grants CMO 50K options expiring 2036 - Stock Titan
Rhythm (RYTM) CMO reports no company stock holdings - Stock Titan
Rhythm Pharmaceuticals (RYTM) Stock Looks Pricey Following Strong IMCIVREE News - Sahm
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer - Sahm
Rhythm Pharmaceuticals: Building A Defensive MC4R Franchise (NASDAQ:RYTM) - Seeking Alpha
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rhythm Pharmaceuticals Inc Stock (RYTM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| David Meeker | Director |
Sep 14 '26 |
Proposed Sale |
104.71 |
50,000 |
5,235,500 |
0 |
| Meeker David P | President and CEO |
Sep 14 '26 |
Sale |
102.67 |
50,000 |
5,133,442 |
239,258 |
| Smith Hunter C | Chief Financial Officer |
Aug 31 '26 |
Option Exercise |
25.79 |
57,187 |
1,474,853 |
176,798 |
| HUNTER SMITH | Officer |
Aug 31 '26 |
Proposed Sale |
107.17 |
62,774 |
6,727,490 |
0 |
| Smith Hunter C | Chief Financial Officer |
Aug 31 '26 |
Sale |
105.46 |
62,774 |
6,619,913 |
114,024 |
| Shulman Joseph | Chief Technical Officer |
Aug 13 '26 |
Sale |
119.75 |
5,079 |
608,210 |
15,915 |
| Garfield Alastair | Chief Scientific Officer |
Aug 13 '26 |
Sale |
117.57 |
7,763 |
912,703 |
2,295 |
| Shulman Joseph | Chief Technical Officer |
Aug 13 '26 |
Option Exercise |
6.80 |
2,024 |
13,763 |
20,994 |
| JOSEPH J SHULMAN | Officer |
Aug 13 '26 |
Proposed Sale |
117.60 |
5,079 |
597,290 |
0 |
| Jennifer Kayden Lee | Officer |
Aug 13 '26 |
Proposed Sale |
117.60 |
75,834 |
8,918,078 |
0 |
2.38%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):